Liquidity and Management’s Plans	9 Months Ended
Sep. 30, 2022
Liquidity and Managements Plans [Abstract]
LIQUIDITY AND MANAGEMENT’S PLANS	NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLANS For the three and nine months ended September 30, 2022, the Company reported a net loss of $7.3 million and $24.4 million, respectively, and negative cash flow from operations for the nine months ended September 30, 2022 of $19.6 million. The Company had an accumulated deficit of $89.7 million and cash and cash equivalents of $13.1 million as of September 30, 2022. The Company has not generated revenues from commercial operations since inception and expects to continue incurring losses for the foreseeable future and needs to raise additional capital to continue the pursuit of its product development. On June 10, 2022, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as agent, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $35.0 million in an “at-the-market” (“ATM”) offering, to or through the agent. Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting sales agent commissions and offering expenses. The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to September 30, 2022. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it hires additional professional and scientific staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has the ability to curtail its presently planned level of operations. The Company plans to seek additional funding through various financing sources, including the sale of its equity and/or debt securities, and/or licensing fees for its technology and co-development and joint ventures with industry partners. The Company believes that its current cash and cash equivalents, and its access to capital through the sale of its equity securities, including the ATM offering, are sufficient to fund its present plan of operations for the next 12 months from the date of filing of these condensed consolidated financial statements. In addition, the Company will consider alternatives to its current business plan that may enable it to achieve its product development goals with a smaller amount of capital.

Liquidity and Management’s Plans

9 Months Ended

Sep. 30, 2022

Liquidity and Managements Plans [Abstract]

NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLANS

For the three and nine months ended September 30, 2022, the Company reported a net loss of $7.3 million and $24.4 million, respectively, and negative cash flow from operations for the nine months ended September 30, 2022 of $19.6 million. The Company had an accumulated deficit of $89.7 million and cash and cash equivalents of $13.1 million as of September 30, 2022. The Company has not generated revenues from commercial operations since inception and expects to continue incurring losses for the foreseeable future and needs to raise additional capital to continue the pursuit of its product development. On June 10, 2022, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as agent, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $35.0 million in an “at-the-market” (“ATM”) offering, to or through the agent. Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting sales agent commissions and offering expenses.

The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to September 30, 2022. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it hires additional professional and scientific staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has the ability to curtail its presently planned level of operations. The Company plans to seek additional funding through various financing sources, including the sale of its equity and/or debt securities, and/or licensing fees for its technology and co-development and joint ventures with industry partners. The Company believes that its current cash and cash equivalents, and its access to capital through the sale of its equity securities, including the ATM offering, are sufficient to fund its present plan of operations for the next 12 months from the date of filing of these condensed consolidated financial statements. In addition, the Company will consider alternatives to its current business plan that may enable it to achieve its product development goals with a smaller amount of capital.